AustralieFrV1, Main, Exploration, bibRecord, 007D14

Immunotherapy of distant metastatic disease

Identifieur interne : 007D14 ( Main/Exploration ); précédent : 007D13; suivant : 007D15

Immunotherapy of distant metastatic disease

Auteurs : D. Schadendorf [Allemagne] ; S. M. Algarra [Espagne] ; L. Bastholt [Danemark] ; G. Cinat [Argentine] ; B. Dreno [France] ; A. M. M. Eggermont [Pays-Bas] ; E. Espinosa [Espagne] ; J. Guo [République populaire de Chine] ; A. Hauschild [Allemagne] ; T. Petrella [Canada] ; J. Schachter [Israël] ; P. Hersey [Australie]

Source :

Annals of Oncology [ 0923-7534 ] ; 2009.

RBID : ISTEX:D54DF89D6D4CE0462ACBAAAE5F1FC30BEBCB56B8

Descripteurs français

Pascal (Inist)
- Antigène CTLA4, Cytokine, Immunisation adoptive, Immunothérapie, Interféron, Interleukine, Maladie, Mélanome malin, Métastase, Stade avancé, Traitement, Vaccin.
Wicri :
- topic : Maladie, Vaccin.

English descriptors

KwdEn :
- Adoptive immunization, Advanced stage, Cytokine, Cytotoxic T lymphocyte antigen 4, Disease, Immunotherapy, Interferon, Interleukin, Malignant melanoma, Metastasis, Treatment, Vaccine.

Abstract

Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon α, and/or with various chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed.

Url:

DOI: 10.1093/annonc/mdp253

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immunotherapy of distant metastatic disease</title>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
</author>
<author><name sortKey="Algarra, S M" sort="Algarra, S M" uniqKey="Algarra S" first="S. M." last="Algarra">S. M. Algarra</name>
</author>
<author><name sortKey="Bastholt, L" sort="Bastholt, L" uniqKey="Bastholt L" first="L." last="Bastholt">L. Bastholt</name>
</author>
<author><name sortKey="Cinat, G" sort="Cinat, G" uniqKey="Cinat G" first="G." last="Cinat">G. Cinat</name>
</author>
<author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B." last="Dreno">B. Dreno</name>
</author>
<author><name sortKey="Eggermont, A M M" sort="Eggermont, A M M" uniqKey="Eggermont A" first="A. M. M." last="Eggermont">A. M. M. Eggermont</name>
</author>
<author><name sortKey="Espinosa, E" sort="Espinosa, E" uniqKey="Espinosa E" first="E." last="Espinosa">E. Espinosa</name>
</author>
<author><name sortKey="Guo, J" sort="Guo, J" uniqKey="Guo J" first="J." last="Guo">J. Guo</name>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
</author>
<author><name sortKey="Petrella, T" sort="Petrella, T" uniqKey="Petrella T" first="T." last="Petrella">T. Petrella</name>
</author>
<author><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J." last="Schachter">J. Schachter</name>
</author>
<author><name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D54DF89D6D4CE0462ACBAAAE5F1FC30BEBCB56B8</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1093/annonc/mdp253</idno>
<idno type="url">https://api.istex.fr/document/D54DF89D6D4CE0462ACBAAAE5F1FC30BEBCB56B8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002788</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002788</idno>
<idno type="wicri:Area/Istex/Curation">002788</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D41</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D41</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Schadendorf D:immunotherapy:of:distant</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712591</idno>
<idno type="RBID">PMC:2712591</idno>
<idno type="wicri:Area/Pmc/Corpus">002241</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002241</idno>
<idno type="wicri:Area/Pmc/Curation">002091</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002091</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002783</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002783</idno>
<idno type="wicri:Area/Ncbi/Merge">000616</idno>
<idno type="wicri:Area/Ncbi/Curation">000616</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000616</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Schadendorf D:immunotherapy:of:distant</idno>
<idno type="wicri:Area/Main/Merge">008408</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0427947</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B23</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003501</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002A68</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002A68</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Schadendorf D:immunotherapy:of:distant</idno>
<idno type="wicri:Area/Main/Merge">008A37</idno>
<idno type="wicri:Area/Main/Curation">007D14</idno>
<idno type="wicri:Area/Main/Exploration">007D14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Immunotherapy of distant metastatic disease</title>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Hospital Essen, Essen</wicri:regionArea>
<wicri:noRegion>Essen</wicri:noRegion>
<wicri:noRegion>Essen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country>
</affiliation>
<affiliation><wicri:noCountry code="syntax">???</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Algarra, S M" sort="Algarra, S M" uniqKey="Algarra S" first="S. M." last="Algarra">S. M. Algarra</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Oncology, Clinica Universitaria de Navarra, Pamplona</wicri:regionArea>
<wicri:noRegion>Pamplona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bastholt, L" sort="Bastholt, L" uniqKey="Bastholt L" first="L." last="Bastholt">L. Bastholt</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Oncology, Odense University Hospital, Odense</wicri:regionArea>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cinat, G" sort="Cinat, G" uniqKey="Cinat G" first="G." last="Cinat">G. Cinat</name>
<affiliation wicri:level="1"><country xml:lang="fr">Argentine</country>
<wicri:regionArea>Department of Oncology, Instituto de Oncologia Angel Roffo, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B." last="Dreno">B. Dreno</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinique of Dermatologie, Hôtel Dieu, Nantes Cedex 01</wicri:regionArea>
<wicri:noRegion>Nantes Cedex 01</wicri:noRegion>
<wicri:noRegion>Nantes Cedex 01</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eggermont, A M M" sort="Eggermont, A M M" uniqKey="Eggermont A" first="A. M. M." last="Eggermont">A. M. M. Eggermont</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Surgical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam</wicri:regionArea>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Espinosa, E" sort="Espinosa, E" uniqKey="Espinosa E" first="E." last="Espinosa">E. Espinosa</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Oncology, Hospital La Paz, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guo, J" sort="Guo, J" uniqKey="Guo J" first="J." last="Guo">J. Guo</name>
<affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Peking University School of Oncology, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Kiel, Kiel</wicri:regionArea>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Petrella, T" sort="Petrella, T" uniqKey="Petrella T" first="T." last="Petrella">T. Petrella</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Sunnybrook Regional Cancer Center, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J." last="Schachter">J. Schachter</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>The Ella Institute for Treatment and Research of Melanoma, Tel Hashomer</wicri:regionArea>
<wicri:noRegion>Tel Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, New South Wales</wicri:regionArea>
<wicri:noRegion>New South Wales</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2009">2009</date>
<biblScope unit="volume">20</biblScope>
<biblScope unit="supplement">suppl_6</biblScope>
<biblScope unit="page" from="41">vi41</biblScope>
<biblScope unit="page" to="50">vi50</biblScope>
</imprint>
<idno type="ISSN">0923-7534</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adoptive immunization</term>
<term>Advanced stage</term>
<term>Cytokine</term>
<term>Cytotoxic T lymphocyte antigen 4</term>
<term>Disease</term>
<term>Immunotherapy</term>
<term>Interferon</term>
<term>Interleukin</term>
<term>Malignant melanoma</term>
<term>Metastasis</term>
<term>Treatment</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antigène CTLA4</term>
<term>Cytokine</term>
<term>Immunisation adoptive</term>
<term>Immunothérapie</term>
<term>Interféron</term>
<term>Interleukine</term>
<term>Maladie</term>
<term>Mélanome malin</term>
<term>Métastase</term>
<term>Stade avancé</term>
<term>Traitement</term>
<term>Vaccin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Maladie</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon α, and/or with various chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Argentine</li>
<li>Australie</li>
<li>Canada</li>
<li>Danemark</li>
<li>Espagne</li>
<li>France</li>
<li>Israël</li>
<li>Pays-Bas</li>
<li>République populaire de Chine</li>
</country>
<region><li>Communauté de Madrid</li>
<li>Hollande-Méridionale</li>
<li>Schleswig-Holstein</li>
</region>
<settlement><li>Kiel</li>
<li>Madrid</li>
<li>Pékin</li>
<li>Rotterdam</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
</noRegion>
<name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
<name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
<name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Algarra, S M" sort="Algarra, S M" uniqKey="Algarra S" first="S. M." last="Algarra">S. M. Algarra</name>
</noRegion>
<name sortKey="Espinosa, E" sort="Espinosa, E" uniqKey="Espinosa E" first="E." last="Espinosa">E. Espinosa</name>
</country>
<country name="Danemark"><noRegion><name sortKey="Bastholt, L" sort="Bastholt, L" uniqKey="Bastholt L" first="L." last="Bastholt">L. Bastholt</name>
</noRegion>
</country>
<country name="Argentine"><noRegion><name sortKey="Cinat, G" sort="Cinat, G" uniqKey="Cinat G" first="G." last="Cinat">G. Cinat</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B." last="Dreno">B. Dreno</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Eggermont, A M M" sort="Eggermont, A M M" uniqKey="Eggermont A" first="A. M. M." last="Eggermont">A. M. M. Eggermont</name>
</region>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Guo, J" sort="Guo, J" uniqKey="Guo J" first="J." last="Guo">J. Guo</name>
</noRegion>
</country>
<country name="Canada"><noRegion><name sortKey="Petrella, T" sort="Petrella, T" uniqKey="Petrella T" first="T." last="Petrella">T. Petrella</name>
</noRegion>
</country>
<country name="Israël"><noRegion><name sortKey="Schachter, J" sort="Schachter, J" uniqKey="Schachter J" first="J." last="Schachter">J. Schachter</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007D14 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007D14 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D54DF89D6D4CE0462ACBAAAE5F1FC30BEBCB56B8
   |texte=   Immunotherapy of distant metastatic disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Immunotherapy of distant metastatic disease

Immunotherapy of distant metastatic disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.